Loading
Kintor Pharmaceutical Ltd. - B Stock: price and insider trades · Hong Kong
1 insider bought €34k of shares over the last 90 days, the latest by Tong Youzhi, filed 20 Oct 2026.
Kintor Pharmaceutical Ltd. - B: what insiders have been doing
Kintor Pharmaceutical Ltd. - B is a Health Care company. Its directors and officers file their transactions with HKEX. Between 22 October 2025 and 22 October 2026, 2 insiders published 35 filings.
Only purchases show up on the open market, 33 purchases in all worth €7.6M, filed by 1 insider. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The largest single trade was a purchase of €4.3M by Tong Youzhi, published on 19 May 2026, equal to 5.0% of the market capitalisation. Among those who bought: 1 senior executive.
With 35 filings in twelve months, the company is more active than the median of 4 filings across the 1,318 companies we follow on the same exchange. Over the whole record (from 2020), the tally stands at 68 purchases and 12 sales.
The clock since the last published purchase (20 October 2026) now reads 4 days. Between a trade and the moment it shows up on HKEX, the median delay is 1 day. The shorter that gap, the sooner other investors can see what insiders have done.
In the same sector, recent insider purchases at UCB also feature in our signals. These figures are compiled from regulatory filings published by HKEX. They describe what insiders did and are not a recommendation.
Insider Decl.
101
Thresholds
n/a
Buy Volume
€112M
68 ops. · all time
Sell Volume
€144M
12 ops. · all time
Who traded when
BuySaleTong Youzhi43 buys1 sale
Since the insiders bought
- +0.6%Entry HK$1.68 · Close 21 Oct 2026 HK$1.69
- +248.1%Entry HK$16.16 · Close at T+365 HK$56.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 25,181 of 26,289 companies
14.3
score / 100
Value9
Quality19
FCF yld-22%
Earn yld-26%
EV/EBITDA·
ROE-118%
Gross mgn25%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$1.59
Analyst consensus
Income statement
RevenueHK$32.7M
Gross profitHK$8M25% margin
EBITDA-HK$165.8M-507% margin
Net income-HK$200.1M-244.6% margin
Valuation
P/Book6.2x
Beta-0.68
Balance sheet & cash
Market capHK$777.3M
Total debtHK$86.6M
Free Cash Flow-HK$170.5M
Debt / Equity122%
Profitability & ownership
ROE-118.5%
ROA-30.3%
% insiders12.0%
% institutions9.9%
Last declaration on 20 October 2026
Declarations101 total
100,000 shares@ HK$1.520.021% mcap0.1% of flowShareXHKGHKEX:DA20261019E00007
Canonical exit: 14 Jan 2027 (T+90)
100,000 shares@ HK$1.500.020% mcap0.8% of flowShareXHKGHKEX:DA20261016E00270
Canonical exit: 13 Jan 2027 (T+90)
145,000 shares@ HK$1.7130.026% mcap0.4% of flowShareXHKGHKEX:DA20260721E00089
Canonical exit: 15 Oct 2026 (T+90)
250,000 shares@ HK$2.0620.059% mcap0.9% of flowShareXHKGHKEX:DA20260626E00073
Canonical exit: 23 Sept 2026 (T+90)
75,000 shares@ HK$2.4360.023% mcap0.3% of flowShareXHKGHKEX:DA20260611E00155
Canonical exit: 7 Sept 2026 (T+90)
50,000 shares@ HK$2.600.016% mcap0.2% of flowShareXHKGHKEX:DA20260608E00319
Canonical exit: 2 Sept 2026 (T+90)
125,000 shares@ HK$2.5180.040% mcap0.5% of flowShareXHKGHKEX:DA20260608E00336
Canonical exit: 3 Sept 2026 (T+90)
42,000 shares@ HK$2.330.012% mcap0.2% of flowShareXHKGHKEX:DA20260528E00204
Canonical exit: 25 Aug 2026 (T+90)
110,000 shares@ HK$2.4750.034% mcap0.5% of flowShareXHKGHKEX:DA20260528E00199
Canonical exit: 24 Aug 2026 (T+90)
190,000 shares@ HK$2.230.053% mcap0.7% of flowShareXHKGHKEX:DA20260528E00212
Canonical exit: 26 Aug 2026 (T+90)
38,000 shares@ HK$2.640.013% mcap0.2% of flowShareXHKGHKEX:DA20260522E00299
Canonical exit: 19 Aug 2026 (T+90)
70,000 shares@ HK$2.741.99% mcap26.7% of flowShareXHKGHKEX:DA20260520E00152
Canonical exit: 17 Aug 2026 (T+90)
170,000 shares@ HK$2.804.97% mcap66.5% of flowShareXHKGHKEX:DA20260519E00135
Canonical exit: 16 Aug 2026 (T+90)
80,000 shares@ HK$2.870.023% mcap0.4% of flowShareXHKGHKEX:DA20260511E00237
Canonical exit: 6 Aug 2026 (T+90)
28,000 shares@ HK$2.6360.0075% mcap0.1% of flowShareXHKGHKEX:DA20260427E00032
Canonical exit: 23 Jul 2026 (T+90)
48,000 shares@ HK$2.7180.013% mcap0.2% of flowShareXHKGHKEX:DA20260422E00263
Canonical exit: 20 Jul 2026 (T+90)
10,000 shares@ HK$2.7470.0028% mcap0.0% of flowShareXHKGHKEX:DA20260420E00094
Canonical exit: 16 Jul 2026 (T+90)
290,000 shares@ HK$2.7550.080% mcap1.3% of flowShareXHKGHKEX:DA20260417E00334
Canonical exit: 15 Jul 2026 (T+90)
50,000 shares@ HK$2.640.016% mcap0.2% of flowShareXHKGHKEX:DA20260410E00214
Canonical exit: 8 Jul 2026 (T+90)
65,000 shares@ HK$2.700.022% mcap0.3% of flowShareXHKGHKEX:DA20260409E00109
Canonical exit: 7 Jul 2026 (T+90)
71,500 shares@ HK$2.5940.023% mcap0.3% of flowShareXHKGHKEX:DA20260407E00049
Canonical exit: 1 Jul 2026 (T+90)
1,250,000 sharesShareXHKGHKEX:DA20260401E00085
856,250 sharesShareXHKGHKEX:DA20260401E00082
150,000 shares@ HK$2.7970.3% of flowShareXHKGHKEX:DA20260123E00373
Canonical exit: 23 Apr 2026 (T+90)
300,000 shares@ HK$2.70330.7% of flowShareXHKGHKEX:DA20260123E00087
Canonical exit: 22 Apr 2026 (T+90)
25 of 101 declarations
About Kintor Pharmaceutical Ltd. - B
Kintor Pharmaceutical Ltd. is a biopharmaceutical company focused on developing innovative treatments for serious diseases. It is listed on the Hong Kong Stock Exchange.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
